Treats Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism. ANDA 214091, held by Sciegen Pharms. Carbidopa; Levodopa.
As of Nov 16, 2026, ANDA 214091 (Carbidopa And Levodopa), held by Sciegen Pharms, was first approved by FDA on Oct 5, 2021, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets, USP are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 5, 2021 | Original application | Approved | None posted |
| Carbidopa And Levodopa25MG;100MG · tablet, extended release;oral | Carbidopa; Levodopa | Rx |
| Carbidopa And Levodopa50MG;200MG · tablet, extended release;oral | Carbidopa; Levodopa | Rx |
| Oct 1, 2026 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 5, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters